Legal & General Group Plc Sells 30,418 Shares of DexCom, Inc. $DXCM

Legal & General Group Plc lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,605,282 shares of the medical device company’s stock after selling 30,418 shares during the period. Legal & General Group Plc’s holdings in DexCom were worth $172,913,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Intermede Investment Partners Ltd bought a new stake in DexCom during the 4th quarter valued at $60,351,000. William Blair Investment Management LLC purchased a new position in shares of DexCom in the 4th quarter worth about $11,387,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of DexCom in the 4th quarter worth about $1,858,000. EverSource Wealth Advisors LLC boosted its holdings in shares of DexCom by 207.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,672 shares of the medical device company’s stock worth $177,000 after buying an additional 1,804 shares during the last quarter. Finally, Evoke Wealth LLC boosted its holdings in shares of DexCom by 14.6% in the 4th quarter. Evoke Wealth LLC now owns 7,401 shares of the medical device company’s stock worth $491,000 after buying an additional 944 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $59.91, for a total value of $101,847.00. Following the sale, the executive vice president directly owned 109,504 shares of the company’s stock, valued at approximately $6,560,384.64. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 32,871 shares of company stock valued at $2,306,638. 0.28% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $85.00 price target on shares of DexCom in a report on Monday, March 9th. Robert W. Baird set a $80.00 price target on shares of DexCom in a report on Friday, May 1st. Raymond James Financial set a $81.00 price objective on shares of DexCom in a report on Friday, May 1st. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a report on Tuesday, March 24th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.21.

DexCom Price Performance

NASDAQ DXCM opened at $70.26 on Thursday. The company has a market cap of $27.11 billion, a PE ratio of 30.03, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm’s 50-day simple moving average is $63.95 and its two-hundred day simple moving average is $66.27.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The company’s revenue was up 15.0% compared to the same quarter last year. Research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.